'AstraZeneca entered China in 1993 and its China headquarters are located in Shanghai. With approximately 13,000 employees throughout the country, the company achieved sales of nearly USD 3.8 billion in 2018. AstraZeneca has invested over USD 1 billion in China, building R&D centre in Shanghai and manufacturing sites in Wuxi and Taizhou, Jiangsu, as well as the China Distribution Center in Wuxi. AstraZeneca China Commercial Innovation Center and Healthcare Internet of Things Innovation Center was established in Wuxi in 2017. In 2019, AstraZeneca announced to co-build the Wuxi International Life Science Innovation Park with the Wuxi municipal government and Wuxi Hi-tech District. AstraZeneca has introduced about 30 innovative medicines covering respiratory, cardiovascular, metabolic, oncology, gastrointestinal and renal diseases in China.
We are committed to delivering growth and TA leadership, accelerating innovative science and being a great place to work, so as to drive business growth in China and realize sustainable development, fulfilling our grand mission of “becoming China’s most trusted healthcare partner by bringing forth innovative solutions to improve the lives of Chinese patients”. '